Friday, January 22, 2016 2:08:54 PM
http://meetinglibrary.asco.org/content/160005-173
Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.
Subcategory: Multidisciplinary Treatment
Category: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Meeting: 2016 Gastrointestinal Cancers Symposium
Session Type and Session Title: Oral Abstract Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Abstract Number: 193
Poster Board Number: Poster Session B Board #A3
Citation: J Clin Oncol 34, 2016 (suppl 4S; abstr 193)
Author(s): Eric Van Cutsem, Heinz-Josef Lenz, Junji Furuse, Josep Tabernero, Volker Heinemann, Tatsuya Ioka, Igor Bazin, Makoto Ueno, Tibor Csõszi, Harpreet Wasan, Bohuslav Melichar, Petr Karasek, Teresa Macarulla, Carmen Guillén Ponce, Ewa Kalinka-Warzocha, Zsolt Horvath, Hans Prenen, Michael Schlichting, Fazal Mehdi, Johanna C. Bendell; University Hospitals Leuven, Leuven, Belgium; USC Norris Comprehensive Cancer Center, Los Angeles, CA; Kyorin University Hospital, Tokyo, Japan; Vall d'Hebron University Hospital, Barcelona, Spain; University of Munich, Munich, Germany; Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka, Japan; N. N. Blokhin Russian Cancer Research Center, Moscow, Russia; Kanagawa Cancer Center, Yokohama, Japan; Jász-Nagykun Szolnok Megyei Hetényi Géza Kórház-Rendelointézet, Szolnok, Hungary; Hammersmith Hospital, Imperial College, London, United Kingdom; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Vall d’Hebron University Hospital, Barcelona, Spain; Hospital Ramón y Cajal, Madrid, Spain; Wojewódzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland; Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Debrecen, Hungary; Merck KGaA, Darmstadt, Germany; EMD Serono, Inc., Billerica, MA; Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN
Abstract Disclosures
Abstract:
Background: Pancreatic ductal adenocarcinoma (PDAC) is invariably diagnosed at an advanced stage and has poor clinical outcome. Hypoxia is a significant prognostic factor in PDAC progression and is associated with poor prognosis. Evofosfamide (Evo, previously known as TH-302) is a hypoxia-activated prodrug of bromo-isophosphoramide mustard (Br-IPM) that is preferentially activated under hypoxic conditions. The addition of Evo to gemcitabine (Gem) significantly improved progression-free survival (PFS) in a randomized phase II trial in advanced PDAC (NCT01144455).
Methods: MAESTRO is an international, randomized, double-blind, placebo-controlled phase III trial of Evo/Gem vs Placebo/Gem in patients (pts) with measurable, locally advanced unresectable or metastatic PDAC (NCT01746979). Evo and Gem were administered intravenously at a dose of 340 mg/m2 and 1,000 mg/m2, respectively, on days 1, 8, and 15 of a 28-day cycle. Treatment continued until disease progression. Key eligibility criteria included ECOG PS 0/1 and no neoadjuvant or adjuvant chemotherapy <6 months prior to entry. The primary endpoint was overall survival (OS) with the study designed to detect a HR of 0.75 with 90% power. Secondary endpoints included PFS and objective response rate (ORR), employing a hierarchical testing procedure with a 2-sided a=0.05 at each level.
Results: A total of 693 pts were randomized to treatment with Evo/Gem (n=xxx) or Placebo/Gem (n=yyy). Baseline pt characteristics were similar between treatment arms. The OS HR was X.XX (95% CI: Y.YY, Z.ZZ; p=A.AAA). Median OS was AA.A months (m) for Evo/Gem vs BB.B m for Placebo/Gem. Median PFS was C.C m and D.D m, respectively (HR E.EE [95% CI: F.FF, G.GG; p = H.HHH). ORR was JJ.J% with Evo/Gem vs KK.K% with Placebo/Gem (p = L.LLL). Grade ≥3 adverse events (AEs) occurring in >5% of pts in treated with Evo/Gem were: TBC.
Conclusions: The data from the MAESTRO trial will make an important contribution to our understanding of PDAC treatment. Clinical trial information: NCT01746979
Nothing I say, post, or do should ever be considered financial advice. It is just my personal opinion. I may be holding a long, short or no position. I am NOT or NEVER have been compensated to post on here and my posts are for entertainment purposes only.
Recent MTEM News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:36:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:26:10 PM
- Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update • GlobeNewswire Inc. • 08/14/2024 08:21:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/13/2024 08:47:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/13/2024 08:44:56 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/13/2024 08:43:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:13:13 PM
- Molecular Templates, Inc. Provides Interim Update • GlobeNewswire Inc. • 06/03/2024 12:11:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:21:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:18:03 PM
- Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update • GlobeNewswire Inc. • 05/15/2024 09:11:54 PM
- Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patien • GlobeNewswire Inc. • 04/09/2024 12:11:00 PM
- Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 03/29/2024 12:21:08 PM
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement • GlobeNewswire Inc. • 03/28/2024 12:11:00 PM
- Molecular Templates, Inc. Provides Interim Update • GlobeNewswire Inc. • 03/04/2024 01:11:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 01:39:50 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:45:31 PM
- Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/08/2024 10:55:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:49:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:34:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:32:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:04:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:13:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:12:59 PM
- Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 11/13/2023 09:11:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM